This brief summarizes the findings from a gap analysis conducted by the Advancing Maternal Immunization (AMI) collaboration of experts, which describes the evidence and policy needs of global and country decision-makers, public health program planners, and implementers that may be involved in maternal respiratory syncytial virus (RSV) vaccine decisions or delivery. This brief focuses specifically on the context of potential introduction in low- and middle-income countries and summarizes relevant evidence across the following broad topic areas: 1) disease, 2) product, 3) health economics and financing, and 4) vaccine service delivery.

AMI is a collaboration of cross-sectoral experts convened by PATH and the World Health Organization with the purpose of advancing RSV maternal immunization.

Related: Advancing Maternal Immunization: A Gap Analysis Report